<DOC>
	<DOCNO>NCT01373554</DOCNO>
	<brief_summary>Dithiolethiones , novel class adenosine monophosphate-activated protein kinase ( AMPK ) activator , prevent insulin resistance AMPK-dependent p70 ribosomal S6 kinase-1 ( S6K1 ) inhibition . And well know modulation S6K1 oltipraz inhibit development insulin resistance hyperglycemia AMPK-S6K1 pathway.Also research report LXRg ( member nuclear hormone receptor ) -mediated increase SREBP-1c ( sterol regulatory element-binding protein-1c gene ) promote expression lipogenic gene enhance fatty acid synthesis oltipraz inhibits LXRg SREBP-c . Therefore , Oltipraz inhibit fatty acid synthesis AMPK-S6K1 pathway LXRg-SREBP-1c pathway liver .</brief_summary>
	<brief_title>Efficacy Safety Oltipraz Patients With Non-alcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Oltipraz</mesh_term>
	<criteria>Patients 18 , 75 year age Patients nonalcoholic fatty liver disease Over 2 ratio AST ALT Type 1 diabetes mellitus ( insulindependent diabetes mellitus ) Disorder liver function exception nonalcoholic fatty liver ( e.g . Virus infection , biliary atresia , autoimmune hepatitis etc . ) Patients take drug induce fatty liver 3 month within 1 year participation study ; amiodarone , tamoxifen , methotrexate , tetracycline , glucocorticoid , anabolic steroid , usual dose estrogen hormone replacement therapy valproate Patients take medication could affect treatment nonalcoholic steatohepatitis : insulin , insulin sensitizer ( metformin , thiazolidinedione ) , high dose vitamin E , high dose UDCA , pentoxifylline , SAMe , Betaine , type Statin , type fibrate orlistat Patients Bariatric surgery less 6 month prior participation study Patients judge investigator participation study difficult due disease follow ; hepatic cirrhosis , Wilson 's disease , malignant tumor , serious metabolic disease , severe renal disease , severe pulmonary disease , severe cardiovascular disease , severe nervous disease/psychiatric disorder , muscle disease etc Any history immune disorder affect change cytokine : inflammatory bowel disease , autoimmune thrombocytopenic purpura , system lupus erythematosus , autoimmune hemolytic anemia , severe psoriasis , rheumatic arthritis etc Patients receive treatment may affect liver function within 1 month prior participation study Patient administer investigational product within 1 month prior participation study Patient allow get MRS test : pacemaker , shunt etc Pregnant nursing woman Patient consider ineligible participation study Investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>